{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~76 mi. (Guadalajara, Mexico, +144 more cities)
facility
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0610)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~76 mi. (Guadalajara, Mexico, +158 more cities)
facility
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0500)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~76 mi. (Guadalajara, Mexico, +122 more cities)
facility
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0401)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~76 mi. (Guadalajara, Mexico, +137 more cities)
facility
Onco-Hematologia de Occidente ( Site 0716)
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
city
~76 mi. (Guadalajara, Mexico, +112 more cities)
facility
Hospital Civil De Guadalajara Juan I Menchaca
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~76 mi. (Guadalajara, Mexico, +105 more cities)
facility
Actualidad Basada en la Investigacion del Cancer ( Site 2903)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~77 mi. (Zapopan, Mexico, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types